The agreement settles ongoing patent litigation in the U.S. District Court of New Jersey. It allows Biocon Biologics to market biosimilars to Amgen’s Prolia (osteoporosis) and Xgeva (cancer bone disease).
The FDA approved both drugs in September 2025 and granted them provisional interchangeability.
CEO Shreehas Tambe said the settlement expands Biocon's oncology portfolio and marks its entry into bone health. He added the launch will widen patient access to advanced biologics and strengthen Biocon’s role as a global biosimilar leader.
Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.
In its latest financial results, Biocon reported a 95.2% decline in consolidated net profit to Rs 31.40 crore despite a 15.8% jump in net sales to Rs 3,910.10 crore in Q1 FY26 compared to Q1 FY25.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."